ReviewMedical cannabis and cannabinoids2020
An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK?
Review in Medical cannabis and cannabinoids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cannabis and cannabinoids in dermatology: a systematic review and meta-analysis of quantitative outcomes.Frontiers in pharmacology · 2025Pooled it
- Cannabis and psychosis: minimising harm while maximising therapeutic potential.The British journal of psychiatry : the journal of mental science · 2026Article
- The Regulatory Environment Surrounding Cannabis Medicines in the EU, the USA, and Australia.Pharmaceutics · 2025Article
- Assessing the Market Readiness for Medical Cannabis in Greece: A Qualitative Study of Patient Perspectives.Medicines (Basel, Switzerland) · 2025Article
- The Cost Effectiveness of Adjunctive Medical Cannabis Therapy in the Treatment of Moderate Post-Traumatic Stress Disorder.Clinical drug investigation · 2025Article
- Observational
- Public understanding of medical cannabis in Poland 7 years after legalization: findings from a cross-sectional study.Frontiers in public health · 2025Article
- Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts.Pain and therapy · 2024Review
- Medicinal cannabis - has it found a place in palliative care?Palliative care and social practice · 2024Article
- Cannabis and cannabinoids in dermatology: protocol for a systematic review and meta-analysis of quantitative outcomes.BMJ open · 2023Article
- Conflicting forces in the implementation of medicinal cannabis regulation in Uruguay.Journal of cannabis research · 2023Article
- Reasonable access: important characteristics and perceived quality of legal and illegal sources of cannabis for medical purposes in Canada.Journal of cannabis research · 2023Article
- Observational
- Medical cannabis, CBD wellness products and public awareness of evolving regulations in the United Kingdom.Journal of cannabis research · 2022Article
- A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products.Cannabis and cannabinoid research · 2022Article
- Endometriosis and Cannabis Consumption During the COVID-19 Pandemic: An International Cross-Sectional Survey.Cannabis and cannabinoid research · 2022Article
- Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products.International journal of environmental research and public health · 2022Article
- Medical cannabis regulation: an overview of models around the world with emphasis on the Brazilian scenario.Journal of cannabis research · 2022Review
- UnderstandingPlants (Basel, Switzerland) · 2022Review
- Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21.Psychopharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper evaluates current regulatory regimes of medical cannabis using peer-reviewed and grey literature as well as personal communications. Despite the legalization of medical cannabis in the UK in November 2018, patients still lack access to the medicine, with fewer than 10 NHS prescriptions having been written to date. We look at six countries that have been at the forefront of prescribing medical cannabis, including case studies of the three largest medical cannabis markets in the EU: Germany, Italy, and the Netherlands. Canada, Israel and Australia add global examples. These countries have a more successful history of prescribing medical cannabis than the UK. Their legislations are outlined and numbers of medical cannabis prescriptions are provided to give an indication of how successful their regulatory regime has been in providing patient access. Evaluating countries' medical cannabis regulations allows us to offer implications for lessons to be learned for the development of a successful medical cannabis regime in the UK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.